GBIM:OTCMKTS
GlobeImmune Inc
$0.00010
0.00%
(0.00) 1 日
9月29日, 15:48:52 GMT-4 · USD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoGBIM の上位の分析情報を生成しています...
時価総額
580.00
平均出来高
1740.00
取引量
0.00
52 週高値
$0.04
52 週安値
$0.00
発行済株式数
575.20万
従業員数
22
時価総額
580.00
平均出来高
1740.00
取引量
0.00
52 週高値
$0.04
52 週安値
$0.00
発行済株式数
575.20万
従業員数
22
ニュース記事
情報源: ウェブソース、ニュース パートナー
日本経済新聞
·
12 分前
米国株、ダウ反発 消費関連やヘルスケアに買い ナスダックも反発
みんかぶ FX/為替
·
1 時間前
ＮＹ各市場 ４時台 ダウ平均は５６２ドル高 シカゴ日経平均先物は６万５７４０円
株探
·
8 時間前
ダウ先物は上昇もナスダック１００は大幅安＝米国株
Infoseek
·
17 時間前
新NISA「つみたて投資枠」人気ランキング！ S&P500が買付金額1位、積立件数1位は？｜Infoseekニュース
プロフィール
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc について